RedHill Biopharma Ltd.

Redhill Biopharma Ltd.

Drug Manufacturers - Specialty & Generic • Healthcare • Tel Aviv, Israel • RDHL (NCM)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

972 3 541 3131 21 Ha’arba’a Street, Israel

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Redhill Biopharma Ltd. (RDHL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
StocksToTrade • Dec 26
RedHill Biopharma Secures Up to $25 Million Standby Equity Facility with YA II PN - TipRanks
TipRanks • Dec 23
Redhill Biopharma stock jumps after court win against Kukbo - Investing.com
Investing.com • Nov 4
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - PR Newswire
PR Newswire • Dec 1
RedHill Biopharma (Nasdaq: RDHL) highlights opaganib CLL study results - Stock Titan
Stock Titan • Dec 15

Other Drug Manufacturers - Specialty & Generic Companies

View All →
Elanco Animal Health Inc logo Elanco Animal Health Inc.
1 layoff tracked
$11.23B market cap
Zoetis Inc. logo Zoetis Inc.
$55.83B market cap
Galderma Group AG/ADR logo Galderma Group AG
$49.28B market cap
TAKEDA PHARMACEUTICAL CO LTD logo Takeda Pharmaceutical Co. Ltd.
$47.02B market cap
Haleon plc logo Haleon PLC
$44.93B market cap
TEVA PHARMACEUTICAL INDUSTRIES LTD logo TEVA Pharmaceutical Industries Ltd.
$32.82B market cap

Frequently Asked Questions

Has RedHill Biopharma Ltd. had layoffs?
No layoff events have been recorded for RedHill Biopharma Ltd. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does RedHill Biopharma Ltd. have?
RedHill Biopharma Ltd. has approximately 35 employees.
What industry is RedHill Biopharma Ltd. in?
RedHill Biopharma Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.
Is RedHill Biopharma Ltd. a publicly traded company?
Yes, RedHill Biopharma Ltd. is publicly traded under the ticker symbol RDHL on the NCM. The company has a market capitalization of approximately $0.01 billion.
Where is RedHill Biopharma Ltd. headquartered?
RedHill Biopharma Ltd. is headquartered in Tel Aviv, Israel at 21 Ha’arba’a Street, Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.